跳至主要内容
临床试验/EUCTR2013-000469-35-NO
EUCTR2013-000469-35-NO进行中(未招募)不适用

Peroral antibiotic treatment of endocarditis - POET

Hillerød Hospital0 个研究点目标入组 400 人开始时间: 2013年5月15日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
400

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Patient admitted to hospital with a diagnosis of left-sided endocarditis as evaluated by a project responsible physician in one of the study sites:
  • -A diagnosis of endocarditis as evaluated by the Duke criteria
  • - Endocarditis with any of the following bacteria:
  • - streptococci
  • -staphylococci
  • -enterococci
  • -Patients >=18 years
  • -Patient has received at least 10 days of correct intravenous antibiotic treatment for bacterial endocarditis, or at least 7 days treatment after surgical intervention
  • -At least 10 days of the antibiotic therapy is left
  • -Temperatur <=37.5 C for 2 days
  • -Decline in blood inflammation parameters (serum-CRP at least 75% comparing peak-value or<;4 x upper limit of normal, and leucocytes at least 25% of peak-value or 15 mia/L) during the antibiotic treatment
  • -No signs of abscess or any worsening of valve function as assessed by transthoracal or transoesophageal ekkocardiography<;48 hours prior to randomisation
  • -Patients that beside the above mentioned also fulfill the modified OPAT (out-patient antibiotic therapy) criteria may be included in the part of the study concerning ambulatory therapy
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 15
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 35

排除标准

  • Previous endocarditis within the last year with the same bacteria
  • (endocarditis-relapse)
  • -Body mass index >40 kg/m2
  • -Heart surgery planned within 6 weeks from randomisation
  • -Any other concurrent infection that needs intravenous antibiotic
  • -Any abdominal/ bowel disease that may reduce uptake of oral
  • - Known reduced immunocompetence such as HIV, or treatment with chemotherapeutics or prednisolon >20mg/day
  • -Subjects incapable of giving informed consent
  • -Subjects with low complience included inravenous drug users

研究者

发起方
Hillerød Hospital

相似试验